Thông tin thuốc của Desonide

Thông tin này không áp dụng cho tất cả các quốc gia. Vui lòng tham khảo thông tin kê toa lưu hành tại Việt Nam.

Thông tin thuốc gốc

Chỉ định và Liều dùng

Topical/Cutaneous
Corticosteroid-responsive dermatoses

Adult: For the relief of inflammatory and pruritic manifestations: As 0.05% cream, ointment, or lotion: Apply thinly onto the affected areas 2-3 times daily (lotion) or 2-4 times daily (cream, ointment) depending on the severity of skin condition. Discontinue therapy once control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be needed. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Topical/Cutaneous
Atopic dermatitis

Adult: For the treatment of mild to moderate cases: As 0.05% foam or gel: Apply thinly to affected areas bid until symptoms resolve. If no improvement is seen within 4 weeks, reassessment of diagnosis may be needed. Max treatment duration: 4 weeks. Dosage and treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: ≥3 months Same as adult dose.

Thận trọng

Not recommended for use in the treatment of diaper dermatitis. Children. Pregnancy and lactation.

Tác dụng không mong muốn

Significant: Hypercortisolism or HPA axis suppression (particularly at high doses for prolonged periods or in younger children), manifestations of Cushing syndrome, hyperglycaemia, or glycosuria; Kaposi sarcoma (prolonged use); growth retardation, intracranial hypertension (in children); local skin reactions including skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection miliaria (when used long-term or with occlusive); increased risk of posterior subcapsular cataracts and glaucoma.
Cardiac disorders: Increased blood pressure.
General disorders and administration site conditions: Irritability.
Hepatobiliary disorders: Abnormal liver function.
Infections and infestations: Viral infection.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Cough, asthma, pharyngitis, URTI.

Phân loại thai kỳ (US FDA)

Topical: C

Thông tin tư vấn bệnh nhân

Avoid contact with the eyes and mucous membranes. Do not apply on open wounds and large surface areas. Avoid use with occlusive dressing. Do not use on the underarm or groin areas of children.

Chỉ số theo dõi

Monitor for HPA axis suppression (e.g. ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test). Monitor for signs and symptoms of bacterial or fungal infection; ocular symptoms.

Tác dụng

Description:
Mechanism of Action: Desonide is a synthetic topical corticosteroid that has anti-inflammatory, antipruritic, and vasoconstrictive properties. The exact mechanism of its anti-inflammatory activity is unclear; however, it may depress the biosynthesis of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A₂ inhibitory proteins (collectively called lipocortins) and sequential inhibition of the release of arachidonic acid.
Pharmacokinetics:
Absorption: Absorbed from normal intact skin; increased percutaneous absorption in occluded or inflamed skin.
Metabolism: Metabolised primarily in the liver.
Excretion: Mainly via urine; bile.

Đặc tính

Bảo quản

Gel: Store between 15-30°C. Foam: Store between 15-30°C. Protect from excessive heat, fire or flames. Storage recommendations may vary among individual products (refer to specific product guidelines).

Phân loại MIMS

Corticoid dùng tại chỗ

Phân loại ATC

D07AB08 - desonide ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.

Tài liệu tham khảo

Anon. Desonide. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 13/11/2023.

Anon. Desonide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/11/2023.

Buckingham R (ed). Desonide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/11/2023.

Desonide Cream or Ointment (Taro Pharmaceuticals, U.S.A., Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 13/11/2023.

Desonide Gel (KMM Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 13/11/2023.

Desonide Lotion (Alembic Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 13/11/2023.

Desonide. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 31/01/2024.

Desowen 0.05% (500 mcg/g) (Galderma Philippines Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 13/11/2023.

Ezenide Lotion 0.05% w/w (Hoe Pharmaceuticals Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 13/11/2023.

Verdeso Aerosol, Foam (Almirall, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 13/11/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Desonide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com